These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 1281381)

  • 21. Combined treatment with serine protease inhibitor aprotinin and matrix metalloproteinase inhibitor Batimastat (BB-94) does not prevent invasion of human esophageal and ovarian carcinoma cells in vivo.
    Della Porta P; Soeltl R; Krell HW; Collins K; O'Donoghue M; Schmitt M; Krüger A
    Anticancer Res; 1999; 19(5B):3809-16. PubMed ID: 10628317
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression, isolation and characterization of recombinant [Arg15,Glu52]aprotinin.
    Auerswald EA; Hörlein D; Reinhardt G; Schröder W; Schnabel E
    Biol Chem Hoppe Seyler; 1988 May; 369 Suppl():27-35. PubMed ID: 2462433
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Occurrence and biochemistry of natural proteinase inhibitors and their significance for the clinical practice].
    Vogel R
    Hippokrates; 1967 Aug; 38(15):577-84. PubMed ID: 5301628
    [No Abstract]   [Full Text] [Related]  

  • 24. Influence of chain shortening on the inhibitor properties of hirudin and eglin c.
    Dodt J; Seemüller U; Fritz H
    Biol Chem Hoppe Seyler; 1987 Nov; 368(11):1447-53. PubMed ID: 3435643
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of proteinase 3 activity by peptides derived from human epidermis.
    Wiedow O; Lüdemann J; Utecht B; Christophers E
    Adv Exp Med Biol; 1993; 336():61-4. PubMed ID: 8296675
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Eglin c, a pharmacologically active elastase inhibitor.
    Schnebli HP; Seemüller U; Fritz H; Maschler R; Liersch M; Virca GD; Bodmer JL; Snider GL; Lucey EC; Stone PG
    Eur J Respir Dis Suppl; 1985; 139():66-70. PubMed ID: 3862612
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aprotinin decreases ischemic damage during coronary revascularization.
    Lazar HL; Bao Y; Tanzillo L; O'Gara P; Reardon D; Price D; Crowley R; Cabral HJ
    J Card Surg; 2005; 20(6):519-23. PubMed ID: 16309402
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Continuing challenges of sepsis research.
    Crowther MA; Marshall JC
    JAMA; 2001 Oct; 286(15):1894-6. PubMed ID: 11597294
    [No Abstract]   [Full Text] [Related]  

  • 29. [The protease inhibitor aprotinin in the therapy of septic shock].
    Putterman C; Bshouty Z; Bursztein S
    Harefuah; 1986 Dec; 111(12):411-4. PubMed ID: 2435623
    [No Abstract]   [Full Text] [Related]  

  • 30. Methylprednisolone and gentamicin effects on hepatosplanchnic blood flow and carbohydrate metabolism in endotoxemic Yucatan miniature pigs.
    Fettman MJ; Hand MS; Chandrasena LG; Cleek JL; Mason RA; Brooks PA; Phillips RW
    Am J Vet Res; 1986 Nov; 47(11):2468-76. PubMed ID: 3538955
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of proteinases with recombinant eglin C during experimental Escherichia coli septicemia in the pig.
    Siebeck M; Hoffmann H; Jochum M; Fritz H
    Eur Surg Res; 1989; 21(1):11-7. PubMed ID: 2653837
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CU-2010--a novel small molecule protease inhibitor with antifibrinolytic and anticoagulant properties.
    Dietrich W; Nicklisch S; Koster A; Spannagl M; Giersiefen H; van de Locht A
    Anesthesiology; 2009 Jan; 110(1):123-30. PubMed ID: 19104179
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stage-specific inhibition of Xenopus embryogenesis by aprotinin, a serine protease inhibitor.
    Iijima R; Yamaguchi S; Homma K; Natori S
    J Biochem; 1999 Nov; 126(5):912-6. PubMed ID: 10544285
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibitory mechanism of serpins. Identification of steps involving the active-site serine residue of the protease.
    Stone SR; Le Bonniec BF
    J Mol Biol; 1997 Jan; 265(3):344-62. PubMed ID: 9018048
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antithrombin effects of native and recombinant hirudins.
    Markwardt F; Stürzebecher J; Glusa E
    Biomed Biochim Acta; 1990; 49(5):399-404. PubMed ID: 2271010
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized blinded study of aprotinin infusion for liver crush injuries in the pig model.
    Thomae KR; Mason DL; Rock WA
    Am Surg; 1997 Feb; 63(2):113-20. PubMed ID: 9012423
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effects of hydrocortisone and aprotinin in endotoxin shock (author's transl)].
    Ebata T; Osanai H; Kobayashi K; Totsuka M; Hayasaka H
    Masui; 1978 May; 27(5):463-6. PubMed ID: 307072
    [No Abstract]   [Full Text] [Related]  

  • 38. Lack of beneficial effects of milrinone in severe septic shock.
    Lindgren S; Almqvist P; Arvidsson D; Montgomery A; Andersson KE; Haglund U
    Circ Shock; 1990 Aug; 31(4):365-75. PubMed ID: 2204496
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Complement activation during storage of blood under normal blood bank conditions. Effects of proteinase inhibitors and leukocyte depletion.
    Schleuning M; Schmid-Haslbeck M; Utz H; Jochum M; Heim M; Mempel W; Wilmanns W
    Blood; 1992 Jun; 79(11):3071-5. PubMed ID: 1375121
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aprotinin improves cerebral protection: evidence from a survival porcine model.
    Anttila V; Hagino I; Iwata Y; Mettler BA; Lidov HG; Zurakowski D; Jonas RA
    J Thorac Cardiovasc Surg; 2006 Oct; 132(4):948-53. PubMed ID: 17000309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.